1. J05 Interim results from cohort 1 of the double-blind, dose-escalation phase I/II clinical trial of amt-130 (HD-genetrx-1) for early-stage huntington's disease (HD). (12th September 2022) Authors: Furr Stimming, Erin; Sung, Victor; Testa, Claudia; Kostyk, Sandra; Ross, Christopher A; Samii, Ali; Geschwind, Michael D; Hall, Deborah; Dayalu, Praveen; Lonser, Russell; Elder, Brad; Larson, Paul S; Cooper, David L; Clarkin, Marcie; Ali, Talaha M; Dolmetsch, Ricardo E Journal: Journal of neurology, neurosurgery and psychiatry Issue: Volume 93(2022)Supplement 1 Page Start: A95 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗